A5048522027- CAR-T cell therapy research
- Silicon Carbide Semiconductor Technologies
- Integrated Circuits and Semiconductor Failure Analysis
- Neonatal and fetal brain pathology
- Fetal and Pediatric Neurological Disorders
- Viral Infectious Diseases and Gene Expression in Insects
- Lymphoma Diagnosis and Treatment
- Prenatal Screening and Diagnostics
- Head and Neck Cancer Studies
- Oral health in cancer treatment
- Pregnancy and preeclampsia studies
- Salivary Gland Disorders and Functions
- Virus-based gene therapy research
- Blood groups and transfusion
- Nanowire Synthesis and Applications
- Multiple Myeloma Research and Treatments
- Complement system in diseases
- Medical Education and Admissions
- Cancer Immunotherapy and Biomarkers
- Neutropenia and Cancer Infections
- Gut microbiota and health
- Birth, Development, and Health
- Clostridium difficile and Clostridium perfringens research
- Chronic Lymphocytic Leukemia Research
- Diversity and Career in Medicine
Sheba Medical Center
2019-2025
Tel Aviv University
2020-2025
Arthur M. Sackler Gallery
2022
Edmond and Lily Safra Children's Hospital
2019
Abstract Oral mucositis (OM) is a common debilitating dose-limiting toxicity of cancer treatment, including hematopoietic stem cell transplantation (HSCT). We hypothesized that the oral microbiome disturbed during allogeneic HSCT, partially accounting for variability in OM severity. Using 16S ribosomal RNA gene sequence analysis, metabolomic profiling, and computational methods, we characterized behavior salivary metabolome 184 patients pre- post-HSCT. Transplantation was associated with...
Disease progression is a substantial challenge in patients with non-Hodgkin lymphoma (NHL) undergoing chimeric antigen receptor T cell (CAR-T) therapy. Here we present InflaMix (INFLAmmation MIXture Model), an unsupervised quantitative model integrating 14 pre-CAR-T infusion laboratory and cytokine measures capturing inflammation end-organ function. Developed using cohort of 149 NHL, revealed inflammatory signature associated high risk CAR-T treatment failure, including increased hazard...
Anti CD19 chimeric antigen receptor (CAR) T-cell therapy has transformed the care of relapsed and refractory aggressive B-cell lymphoma. However, financial toxicity manufacturing time represent barriers to its widespread implementation. Study applicability, toxicity, efficacy a locally produced autologous CD19-directed CAR product were studied. We performed phase 1b/2 clinical trial with point-of-care (POC) that contains CD28 costimulatory domain. Adult patients lymphoma or low-grade who...
Pulmonary function tests (PFT) are recommended for hematopoietic cell transplantation (HCT) evaluation. However, their prognostic value in chimeric antigen receptor T-cell (CAR-T) therapy remains unclear. We assessed the predictive significance of PFTs and pulmonary comorbidity classifications, per Hematopoietic Cell Transplantation-Comorbidity Index (HCT-CI), B-cell lymphoma patients undergoing autologous CD19-CAR-T therapy. Single-center retrospective analysis encompassing 192 with...
Tisagenlecleucel (tisa-cel) is an anti-CD19 chimeric antigen receptor (CAR) T-cell therapy approved for patients with relapsed/refractory large B-cell lymphoma. Outcomes of out-of-commercial specification (OOS) CAR T products are not well characterized. We therefore assessed 37 adult who underwent leukapheresis tisa-cel in a single center. In nine (24%) patients, manufactured was considered OOS. Three them (33%) received after institutional review board approval; 2/9 (22%) did receive due to...
According to the medical literature, it is known that intrauterine growth restriction associated with abnormal fetal brain findings. The aim of this study was assess volume structures in fetuses compared control group and examine effect on birth weight relation volumes these structures.This historical cohort included 26 diagnosed due placental insufficiency. 66 MR imaging scans demonstrating normal structures. supratentorial brain, left right hemispheres, cerebellum were measured using a...
The activity of anti-CD19 chimerci antigen receptor (CAR) T-cell therapy in chronic lymphocytic leukemia (CLL) with Richter's transformation (RT) to aggressive large B-cell lymphoma (LBCL) is largely unknown. In a multicenter retrospective study, we report the safety and efficacy CAR patients RT (N=30) compared (N=283) transformed indolent non-Hodgkin (iNHL) (N=141) between April 2016 January 2023. Two-thirds received prior for CLL before 89% them 2 inhibitors. Toxicities were similar other...
Abstract Background Recruitment to residency programs in hospitals located other than major hubs (“remotely located”) is a challenge many countries. In 2011, the Israeli Ministry of Health launched 10-year financial incentive encourage physicians enroll such hospitals. Nearly 1 billion New Shekels (260 million US$) were invested that program which had only limited success. As new physician association’s collective agreement impending, we aimed measure effectiveness selected incentives...
AbstractPatients with relapsed/refractory follicular lymphoma (R/R-FL) often require multiple treatment lines. We performed a phase 1b/2 single-center clinical trial of autologous point-of-care anti-CD19 chimeric antigen receptor (CAR) T-cells in R/R-FL patients treated ≥ 2 All 26 enrolled received CAR T-cell infusion at median 11 days after leukapheresis. Seventy-seven percent had POD24. At enrollment, disease stage was III-IV 85% the patients, 77% high-risk FLIPI score, and progressive...
Topic: 14. Myeloma and other monoclonal gammopathies - Clinical Background: Anti-BCMA chimeric antigen receptor (CAR) T-cell therapy showed excellent efficacy safety in patients with relapsed/refractory multiple myeloma (R/R MM). Point-of-care (POC) CAR manufacturing abrogates the need for cryopreservation shipment of cells, thus shortening process reducing necessity bridging therapy. Aims: To report outcomes phase 1b/2 single-center clinical trial autologous POC anti-BCMA (pts) R/R MM...
Background Oral mucositis (OM) is a debilitating multifactorial complication of hematopoietic stem cell transplantation (HSCT). We hypothesized that the oral microbiome disturbed during and may partially account for variability in OM severity across patients. Methods In this single-center study, we prospectively collected saliva samples weekly cohort 184 adults undergoing allogeneic HSCT. A total 625 were starting from 7 days before HSCT to 34 post-transplant. Samples underwent 16S rRNA gene...
Definitions of fetal microcephaly and macrocephaly are debatable. A better understanding their long-term prognoses would help guide parental education counseling. This study aimed to explore the correlation between 2D 3D brain MR imaging biometry results neurodevelopmental outcomes.This analysis is a historical cohort study. Fetal was measured on using volumetric semiautomated algorithm. We assessed following structures: supratentorial volume cerebellar volume/supratentorial ratio, in...
Patients with plasma cell disorders (PCD) are at an increased risk for severe morbidity and mortality due to COVID-19. Recent data have suggested that patients hematological malignancies, including those PCD, suboptimal antibody response COVID-19 vaccination. We compared the titers of 213 PCD immunocompetent healthcare workers after second vaccine dose BNT162b2 mRNA vaccine. Blood samples were taken 2-4 weeks vaccination analyzed anti-receptor binding-domain immunoglobulin G (RBD-IgG)...
Introduction: Anti-BCMA chimeric antigen receptor (CAR) T-cell therapy showed excellent efficacy in patients with relapsed/refractory multiple myeloma (R/R MM). Point-of-care (POC) CAR manufacturing abrogates the need for cryopreservation and shipment of cells, thus shortening process reducing necessity bridging therapy. We report outcomes phase 1b/2 single-center clinical trial autologous POC anti-BCMA (pts) R/R MM treated ≥3 prior therapies (NCT05243212). Methods: Pts underwent a single...
Background/Objectives: This study aimed to explore a relationship between the fetal subarachnoid space (SAS) width and various pathologies, employing brain MRI scans. Methods: A retrospective collection of scans 78 fetuses was performed with sonographic indications microcephaly, macrocephaly, or growth restriction (FGR), during 7-year period at single tertiary center. The SAS (named index) manually measured in millimeters ten specific anatomical locations (four axial plane six coronal...